Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces that the Company has successfully completed a directed… Read More »Asarina Pharma has completed a directed share issue of approximately SEK 48 million
Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces its intention to execute a directed share issue… Read More »Asarina Pharma intends to carry out a directed share issue
Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” eller ”Bolaget”) offentliggör idag avsikten att genomföra en riktad nyemission till institutionella investerare… Read More »Asarina Pharma avser att genomföra en riktad nyemission
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine… Read More »First patient included in menstrual migraine study
Asarina Pharma AB (publ) (ASAP: FN Stockholm) meddelade idag att den första patienten inkluderats bolagets fas IIa-studie av Sepranolone vid menstruell migrän (MM). Studien omfattar… Read More »Första patienten inkluderad i menstruell migränstudie
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the last patient was enrolled in the Phase IIb study for its first-in-class compound Sepranolone for… Read More »Last Patient In for landmark PMDD study
Asarina Pharma AB (publ) (ASAP: FN Stockholm) meddelade idag att den sista patienten inkluderats i bolagets i fas IIb-studie av läkemedelssubstansen Sepranolone i premenstruellt dysforiskt… Read More »Sista patienten inkluderad i unik PMDS-studie
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announces the FDA has approved the IND for its lead compound Sepranolone in menstrual migraine. It is… Read More »Sepranolone receives FDA IND approval in menstrual migraine
Asarina Pharma AB (publ) (ASAP: FN Stockholm) tillkännagav idag att FDA har godkänt bolagets IND-ansökan för sin ledande läkemedelskandidat Sepranolone i menstruell migrän. Godkännandet är… Read More »Sepranolone får IND-godkännande från FDA i menstruell migrän
Stockholm, April 2, 2019: Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects. The… Read More »Asarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects